

# Susanna B Park

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7285202/publications.pdf>

Version: 2024-02-01

92  
papers

3,908  
citations

196777

29  
h-index

145109

60  
g-index

92  
all docs

92  
docs citations

92  
times ranked

4732  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. <i>Journal of Cancer Survivorship</i> , 2023, 17, 222-236.   | 1.5 | 20        |
| 2  | The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 223-232.  | 1.5 | 16        |
| 3  | Optimal outcome measures for assessing exercise and rehabilitation approaches in chemotherapy-induced peripheral-neurotoxicity: Systematic review and consensus expert opinion. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 65-76.         | 1.4 | 11        |
| 4  | Mechanisms, Mediators, and Moderators of the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy. <i>Cancers</i> , 2022, 14, 1224.   | 1.7 | 20        |
| 5  | Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 171, 103575. | 2.0 | 18        |
| 6  | Differences in nerve excitability properties across upper limb sensory and motor axons. <i>Clinical Neurophysiology</i> , 2022, 136, 138-149.  | 0.7 | 2         |
| 7  | Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2022, 30, 5965-5974.  | 1.0 | 2         |
| 8  | Evaluation of the psychometric properties of patient-reported and clinician-reported outcome measures of chemotherapy-induced peripheral neuropathy: a COSMIN systematic review protocol. <i>BMJ Open</i> , 2022, 12, e057950.                       | 0.8 | 1         |
| 9  | Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. <i>Quality of Life Research</i> , 2022, 31, 3091-3107.                 | 1.5 | 11        |
| 10 | Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. <i>Supportive Care in Cancer</i> , 2021, 29, 1103-1110.  | 1.0 | 12        |
| 11 | A cross-sectional study of ocular surface discomfort and corneal nerve dysfunction after paclitaxel treatment for cancer. <i>Scientific Reports</i> , 2021, 11, 1786.  | 1.6 | 10        |
| 12 | A Cross-Sectional Study of Sub-Basal Corneal Nerve Reduction Following Neurotoxic Chemotherapy. <i>Translational Vision Science and Technology</i> , 2021, 10, 24.   | 1.1 | 15        |
| 13 | Characteristics and patterns of pediatric chemotherapy-induced peripheral neuropathy: A systematic review. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100420.   | 0.7 | 8         |
| 14 | Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. <i>JAMA Network Open</i> , 2021, 4, e2036695.  | 2.8 | 49        |
| 15 | Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. <i>Oncologist</i> , 2021, 26, 366-374.   | 1.9 | 12        |
| 16 | A Versatile Fluorescent Sensor Array for Platinum Anticancer Drug Detection in Biological Fluids. <i>ACS Sensors</i> , 2021, 6, 1261-1269.   | 4.0 | 20        |
| 17 | Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences. <i>Supportive Care in Cancer</i> , 2021, 29, 6379-6387.  | 1.0 | 4         |
| 18 | Effect of exercise on neuromuscular toxicity in oxaliplatin-treated mice. <i>Muscle and Nerve</i> , 2021, 64, 225-234.   | 1.0 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.   | 1.5 | 16        |
| 20 | Corneal nerve changes following treatment with neurotoxic anticancer drugs. <i>Ocular Surface</i> , 2021, 21, 221-237.   | 2.2 | 7         |
| 21 | Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 821-828.             | 2.3 | 24        |
| 22 | Chemotherapy and peripheral neuropathy. <i>Neurological Sciences</i> , 2021, 42, 4109-4121.  | 0.9 | 21        |
| 23 | Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021, 99, 102241.                             | 3.4 | 29        |
| 24 | Systematic Review of Exercise for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy. , 2021, , 183-241.  |     | 6         |
| 25 | Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel. <i>Scientific Reports</i> , 2021, 11, 22884.  | 1.6 | 11        |
| 26 | Measurement of axonal excitability: Consensus guidelines. <i>Clinical Neurophysiology</i> , 2020, 131, 308-323.  | 0.7 | 63        |
| 27 | Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. <i>Journal of Pain</i> , 2020, 21, 44-58.   | 0.7 | 22        |
| 28 | Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. <i>Hematological Oncology</i> , 2020, 38, 229-243.  | 0.8 | 28        |
| 29 | Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. <i>Clinical Neurophysiology</i> , 2020, 131, 783-790.                              | 0.7 | 5         |
| 30 | Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1005-1016. | 1.4 | 16        |
| 31 | Peripheral nerve maturation and excitability properties from early childhood: Comparison of motor and sensory nerves. <i>Clinical Neurophysiology</i> , 2020, 131, 2452-2459.                                    | 0.7 | 3         |
| 32 | Isaacs syndrome: the frontier of neurology, psychiatry, immunology and cancer. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1243-1244.   | 0.9 | 13        |
| 33 | Acute changes in nerve excitability following oxaliplatin treatment in mice. <i>Journal of Neurophysiology</i> , 2020, 124, 232-244.   | 0.9 | 9         |
| 34 | Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. <i>Supportive Care in Cancer</i> , 2020, 28, 4459-4466.  | 1.0 | 19        |
| 35 | Peripheral neuropathy in hematologic malignancies – Past, present and future. <i>Blood Reviews</i> , 2020, 43, 100653.   | 2.8 | 16        |
| 36 | The impact of anticancer drugs on the ocular surface. <i>Ocular Surface</i> , 2020, 18, 403-417.   | 2.2 | 13        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Electrophysiological and phenotypic profiles of taxane-induced neuropathy. <i>Clinical Neurophysiology</i> , 2020, 131, 1979-1985.   | 0.7 | 14        |
| 38 | Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 1023-1032.   | 0.6 | 21        |
| 39 | Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969. | 0.9 | 43        |
| 40 | Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 360-361.                 | 1.4 | 4         |
| 41 | Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.                                       | 1.4 | 11        |
| 42 | Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S40-S51.   | 1.4 | 33        |
| 43 | The Toxic Neuropathy Consortium of the Peripheral Nerve Society. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S4-S5.  | 1.4 | 3         |
| 44 | Overview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S13-S25.   | 1.4 | 34        |
| 45 | Amyotrophic lateral sclerosis diagnostic index. <i>Neurology</i> , 2019, 92, e536-e547.  | 1.5 | 17        |
| 46 | Mobility in survivors with chemotherapy-induced peripheral neuropathy and utility of the 6-min walk test. <i>Journal of Cancer Survivorship</i> , 2019, 13, 495-502.   | 1.5 | 14        |
| 47 | Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.  | 1.0 | 30        |
| 48 | Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2019, 27, 3849-3857.  | 1.0 | 56        |
| 49 | 009...Axonal excitability properties in dravet's syndrome reflect effect of loss of sodium channels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, A4.1-A4.   | 0.9 | 0         |
| 50 | Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 949-955.  | 2.3 | 27        |
| 51 | Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. <i>Clinical Neurophysiology</i> , 2018, 129, 974-980.  | 0.7 | 15        |
| 52 | Oxaliplatin and neuropathy: A role for sodium channels. <i>Clinical Neurophysiology</i> , 2018, 129, 670-671.  | 0.7 | 6         |
| 53 | Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. <i>Muscle and Nerve</i> , 2018, 57, 615-621.  | 1.0 | 2         |
| 54 | Neurofascin-155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. <i>Muscle and Nerve</i> , 2018, 57, 848-851.  | 1.0 | 37        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer. <i>JAMA Neurology</i> , 2018, 75, 980.  | 4.5 | 73        |
| 56 | Inflammatory neuropathies: all shapes and sizes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1128-1128.   | 0.9 | 1         |
| 57 | Comparison of cross-sectional areas and distal-proximal nerve ratios in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2018, 58, 777-783.  | 1.0 | 27        |
| 58 | Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. <i>Clinical Neurophysiology</i> , 2018, 129, 2162-2169.                           | 0.7 | 15        |
| 59 | 004â€¦Mechanisms of nerve dysfunction in inflammatory neuropathies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A3.1-A3.  | 0.9 | 0         |
| 60 | Differentiating lower motor neuron syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 474-483.  | 0.9 | 93        |
| 61 | Immune-mediated processes implicated in chemotherapy-induced peripheral neuropathy. <i>European Journal of Cancer</i> , 2017, 73, 22-29.   | 1.3 | 130       |
| 62 | Too fast: rare neuropathic pain state associated with easy activation of NaV1.9. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 194-194.                               | 0.9 | 0         |
| 63 | Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. <i>Journal of Neurology</i> , 2017, 264, 882-890.  | 1.8 | 23        |
| 64 | Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. <i>Clinical Neurophysiology</i> , 2017, 128, 1166-1175.   | 0.7 | 50        |
| 65 | Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. <i>Supportive Care in Cancer</i> , 2017, 25, 3485-3493. | 1.0 | 59        |
| 66 | Emerging therapies and challenges in spinal muscular atrophy. <i>Annals of Neurology</i> , 2017, 81, 355-368.  | 2.8 | 157       |
| 67 | Cardiometabolic health and risk of amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2017, 56, 721-725.   | 1.0 | 8         |
| 68 | Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. <i>Clinical Neurophysiology</i> , 2017, 128, 2022-2028.  | 0.7 | 25        |
| 69 | Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. <i>Muscle and Nerve</i> , 2017, 55, 424-427.   | 1.0 | 10        |
| 70 | Characterisation of Immune and Neuroinflammatory Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. <i>PLoS ONE</i> , 2017, 12, e0170814.                                   | 1.1 | 177       |
| 71 | Fast-adapting mechanoreceptors are important for force control in precision grip but not for sensorimotor memory. <i>Journal of Neurophysiology</i> , 2016, 115, 3156-3161.                  | 0.9 | 9         |
| 72 | Pediatric chemotherapy induced peripheral neuropathy: A systematic review of current knowledge. <i>Cancer Treatment Reviews</i> , 2016, 50, 118-128.   | 3.4 | 69        |

| #  | ARTICLE  | IF    | CITATIONS |
|----|--|-------|-----------|
| 73 | Motor cortical function determines prognosis in sporadic ALS. <i>Neurology</i> , 2016, 87, 513-520.  | 1.5   | 76        |
| 74 | Acute bulbar, neck and limb weakness with monospecific anti-IGT1a antibody: A rare localized subtype of Guillain-Barré syndrome. <i>Muscle and Nerve</i> , 2016, 53, 143-146.      | 1.0   | 2         |
| 75 | Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. <i>Clinical Neurophysiology</i> , 2016, 127, 2355-2361.                | 0.7   | 33        |
| 76 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. <i>EBioMedicine</i> , 2015, 2, 1916-1922.                 | 2.7   | 25        |
| 77 | Reply: Biomarkers of "acute-onset" chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2015, 138, e336-e336.   | 3.7   | 0         |
| 78 | Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 973-985.              | 0.9   | 320       |
| 79 | Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. <i>Brain</i> , 2014, 137, 2155-2163.  | 3.7   | 35        |
| 80 | Axonal dysfunction with voltage gated potassium channel complex antibodies. <i>Experimental Neurology</i> , 2014, 261, 337-342.  | 2.0   | 14        |
| 81 | Chemotherapy-induced peripheral neurotoxicity: A critical analysis. <i>Ca-A Cancer Journal for Clinicians</i> , 2013, 63, 419-437.   | 157.7 | 547       |
| 82 | Impact of oxaliplatin-induced neuropathy: a patient perspective. <i>Supportive Care in Cancer</i> , 2012, 20, 2959-2967.   | 1.0   | 93        |
| 83 | The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1189-1190.  | 1.1   | 2         |
| 84 | Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. <i>Muscle and Nerve</i> , 2011, 43, 367-374.                               | 1.0   | 69        |
| 85 | Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. <i>Archives of Neurology</i> , 2011, 68, 862. | 4.9   | 63        |
| 86 | Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. <i>Oncologist</i> , 2011, 16, 708-716.  | 1.9   | 171       |
| 87 | Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. <i>Brain</i> , 2011, 134, 3185-3197.                                     | 3.7   | 35        |
| 88 | Dose Effects of Oxaliplatin on Persistent and Transient Na <sup>+</sup> Conductances and the Development of Neurotoxicity. <i>PLoS ONE</i> , 2011, 6, e18469.                      | 1.1   | 61        |
| 89 | Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. <i>Oncology</i> , 2009, 77, 342-348.  | 0.9   | 21        |
| 90 | Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. <i>Journal of Clinical Oncology</i> , 2009, 27, 1243-1249.                        | 0.8   | 153       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | Axonal ion channels from bench to bedside: A translational neuroscience perspective. <i>Progress in Neurobiology</i> , 2009, 89, 288-313. | 2.8 | 144       |
| 92 | Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. <i>Brain</i> , 2009, 132, 2712-2723. | 3.7 | 198       |